Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.
Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A, Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Borin L, Di Tucci AA, Zhang H, Sprangers M, Vignetti M, Mandelli F. Efficace F, et al. Among authors: di tucci aa. Cancer. 2018 Mar 15;124(6):1251-1259. doi: 10.1002/cncr.31193. Epub 2017 Dec 12. Cancer. 2018. PMID: 29231969 Free article.
Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes.
Efficace F, Gaidano G, Sprangers M, Cottone F, Breccia M, Voso MT, Caocci G, Stauder R, Di Tucci AA, Sanpaolo G, Selleslag D, Angelucci E, Platzbecker U, Mandelli F. Efficace F, et al. Among authors: di tucci aa. Ann Oncol. 2014 Feb;25(2):447-54. doi: 10.1093/annonc/mdt557. Ann Oncol. 2014. PMID: 24478321 Free article.
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S. Angelucci E, et al. Among authors: di tucci aa. Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10. Eur J Haematol. 2014. PMID: 24580147 Clinical Trial.
Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.
Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, Quaresmini G, Di Tucci AA, Volpe A, Cilloni D, Quarta G, Sanpaolo G, Rivellini F, Salvi F, Molteni A, Voso MT, Alimena G, Fenu S, Mandelli F, Angelucci E. Efficace F, et al. Among authors: di tucci aa. BMJ Support Palliat Care. 2016 Mar;6(1):80-8. doi: 10.1136/bmjspcare-2014-000726. Epub 2014 Sep 9. BMJ Support Palliat Care. 2016. PMID: 25204541
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
Voso MT, Santini V, Finelli C, Musto P, Pogliani E, Angelucci E, Fioritoni G, Alimena G, Maurillo L, Cortelezzi A, Buccisano F, Gobbi M, Borin L, Di Tucci A, Zini G, Petti MC, Martinelli G, Fabiani E, Fazi P, Vignetti M, Piciocchi A, Liso V, Amadori S, Leone G. Voso MT, et al. Clin Cancer Res. 2009 Aug 1;15(15):5002-7. doi: 10.1158/1078-0432.CCR-09-0494. Epub 2009 Jul 28. Clin Cancer Res. 2009. PMID: 19638460 Free article. Clinical Trial.
Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes.
Piciocchi A, Sargentini V, Cotugno F, Bontempi K, Beltrami G, Di Tucci AA, Riva M, Quaresmini G, Vallisa D, Finelli C, Borin L, Fazi P, Vignetti M, Angelucci E. Piciocchi A, et al. Among authors: di tucci aa. Eur J Haematol. 2019 May;102(5):442-443. doi: 10.1111/ejh.13222. Epub 2019 Mar 13. Eur J Haematol. 2019. PMID: 30776156 No abstract available.
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Clavio M, Crisà E, Miglino M, Guolo F, Ceccarelli M, Salvi F, Allione B, Ferrero D, Balleari E, Finelli C, Poloni A, Selleri C, Danise P, Cilloni D, Di Tucci AA, Cametti G, Freilone R, Fanin R, Bigazzi C, Zambello R, Crugnola M, Oliva EN, Centurioni R, Alesiani F, Catarini M, Castelli A, Abbadessa A, Capalbo SF, Musto P, Angelucci E, Santini V. Clavio M, et al. Among authors: di tucci aa. Cancer. 2021 Jun 15;127(12):2015-2024. doi: 10.1002/cncr.33472. Epub 2021 Mar 19. Cancer. 2021. PMID: 33739457 Free article.
A genome-wide association study by ImmunoChip reveals potential modifiers in myelodysplastic syndromes.
Danjou F, Fozza C, Zoledziewska M, Mulas A, Corda G, Contini S, Dore F, Galleu A, Di Tucci AA, Caocci G, Gaviano E, Latte G, Gabbas A, Casula P, Delogu LG, La Nasa G, Angelucci E, Cucca F, Longinotti M. Danjou F, et al. Among authors: di tucci aa. Exp Hematol. 2016 Nov;44(11):1034-1038. doi: 10.1016/j.exphem.2016.07.005. Epub 2016 Jul 21. Exp Hematol. 2016. PMID: 27449989 Free article.
24 results